Keytruda pembrolizumab: Additional Phase II data

Data from 92 evaluable patients with recurrent or metastatic SCCHN who progressed on platinum-based therapy and cetuximab in the open-label Phase II KEYNOTE-055 trial

Read the full 249 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE